Vaccine Types by Dai, Xiaoxia et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Xiaoxia Dai, Yongmin Xiong, Na Li and Can Jian
Abstract
There are several different types of vaccines. Each type is designed to teach your 
immune system how to fight off certain kinds of germs and the serious diseases they 
cause. There are four main types of vaccines: live attenuated vaccines; inactivated 
vaccines; subunit, recombinant, polysaccharide, and conjugate vaccines; and toxoid 
vaccines.
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1. Introduction
Vaccines are biologics that provide active adaptive immunity against specific dis-
eases. Vaccines usually contain drugs that resemble the microorganisms responsible 
for the disease and are often made from one of the killed or attenuated microorgan-
isms, their toxins, or their surface proteins, introduced by mouth, by injection, 
or by nasal spray to stimulate the immune system in us and recognize the foreign 
agents and destroy them.
There are many success stories in vaccine. The first vaccine, against smallpox, 
a disease that had killed millions of people over the centuries by British physician 
Edward Jenner in 1796 [1], was derived from the benign cowpox virus, which 
provided immunity to small pox. In 1980, following an historic global campaign 
of surveillance and vaccination, the World Health Assembly declared smallpox 
eradicated. In the nineteenth and twentieth centuries, scientists following Jenner’s 
model developed new vaccines to fight numerous deadly diseases, including polio, 
whooping cough, measles, tetanus, yellow fever, typhus, rubella mumps, varicella, 
and hepatitis B and many others [2]. Rabies was the first virus attenuated in a lab to 
create a vaccine for humans.
The vaccine exposes humans to very small and safe amounts of attenuated or 
killed viruses and bacteria. When you are exposed to it in later life, the immune 
system will learn to recognize and attack infections. So you will not get sick, or you 
may be infected lightly. During the process of immunity development, the body 
produces antibodies against specific microorganisms and creates defense. The next 
time the person encounters that microorganism, the antibody prevents him from 
causing disease or alleviates the severity of the disease, regardless of the way that a 
vaccine is made.
Vaccines are the most cost-effective healthcare interventions known to prevent 
death and disease. A dollar spent on a childhood vaccination not only helps save a 
life but greatly reduces spending on future healthcare. According to a new study 
from the University of North Carolina at Chapel Hill, vaccination efforts made in 
the world’s poorest countries since 2001 will have prevented 20 million deaths and 
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saved $350 billion in healthcare costs by 2020 [3]. There are still numerous diseases 
causing globally significant morbidity and mortality, for which no vaccines are 
available. Millions of people worldwide die of malaria, tuberculosis, and AIDS 
every year, diseases without effective vaccines. This chapter describes the vaccine 
types now in use and that may lead to the vaccines of the future.
2. Different types of vaccines
There are several different types of vaccines. Each type is designed to boost 
your immune system and prevent serious, life-threatening diseases. Four types of 
vaccines are currently available:
• live attenuated vaccines;
• inactivated vaccines;
• subunit, recombinant, polysaccharide, and conjugate vaccines; and
• toxoid vaccines.
2.1 Live attenuated vaccines
Live attenuated vaccines contain a version of the living virus that has been weak-
ened so that it does not cause serious disease in people with healthy immune systems. 
Live attenuated vaccines can be made in several different ways. The most common 
methods involve passing the disease-causing virus through a series of cell cultures or 
animal embryos (typically chick embryos). Viruses are often attenuated by growing 
them in cells that they do not normally grow in for many generations. With each 
passage, the virus becomes better at replicating in new cells but loses its ability to 
replicate in human cells. Eventually, the attenuated virus will be less able to live in 
human cells and can be used in a vaccine. This method selects mutants that are more 
suitable for growth under abnormal culture conditions and is therefore less suit-
able for growth in natural hosts. Therefore, when attenuated viruses are given to a 
human, they are not able to replicate enough to cause illness like they would naturally 
but will still provoke an immune response that can protect against future infection. 
Albert Sabin’s oral polio vaccine and measles, rubella, mumps, and varicella vaccines 
are all achieved by in vitro cell culture passage selection clones. The poliovirus used 
in the Sabin vaccine is attenuated by the growth of monkey kidney epithelial cells. 
The measles vaccine contains a strain of rubella virus that grows in duck embryo cells 
and later grows in human cell lines [4–8]. Another live vaccine that has so far only 
been used in the military to prevent epidemic pneumonia includes adenoviruses 4 
and 7 grown in human diploid cell lines and orally administered for replication in 
the intestine [9]. Other live vaccines that are attenuated in cell culture passages are 
attenuated monovalent rotavirus vaccines in Vero cells [10] and Japanese encephalitis 
virus strain SA14-14-2 [11]. Some viral vaccines are grown in chicken eggs; live 
attenuated influenza vaccine and yellow fever vaccines are currently produced in 
embryonated hen’s eggs, a method developed in the late 1930s [12, 13].
Live attenuated vaccines have advantages and disadvantages. Live attenuated 
vaccines are ideal for teaching the immune system against specific viruses because 
they are closest to natural infections. They often require only a single immuniza-
tion, eliminating the need for repeated boosters. And these vaccines are relatively 
easy to create for certain viruses.
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The Sabine polio vaccine consists of three attenuated poliovirus strains that are 
orally administered to children in sugar cube or sugar liquid. The attenuated virus 
colonizes the gut and produces protective immunity against all three virulent polio-
virus strains. Unlike most other attenuated vaccines that require a single immuniza-
tion dose, the Sabin polio vaccine requires a booster because the three attenuated 
polioviruses in the vaccine interfere with each other’s replication in the gut.
The main disadvantage of attenuated vaccines is the possibility they will revert to a 
virulent form and cause disease. These vaccines cannot be administered to people with 
weakened immune systems due to cancer, HIV, or other immune system depressing 
diseases. Attenuated vaccines also may be associated with complications similar to 
those seen in the natural disease. Live attenuated vaccines usually have to be refriger-
ated and protected from light. It can be difficult to ship these vaccines overseas and use 
them in places where there is lack of refrigeration. This technique does not work well 
for bacteria; therefore there are few live bacterial vaccines. The virus is very simple, 
but for bacteria, which have thousands of gene, is at least a hundred times larger than 
a typical virus. This makes bacteria more difficult to control and manipulate than 
viruses. Currently, scientists are trying to remove key genes from certain bacteria in 
order to create a weakened version for vaccines.




• oral polio vaccine (not used in the USA);
• influenza vaccine (nasal spray) FluMist;
• varicella (chickenpox) vaccine;
• shingles vaccine;
• yellow fever vaccine;
• adenovirus oral vaccine (military); and
• Vaccinia vaccine.
2.2 Inactivated vaccines
Another common method of vaccine production is inactivation of the pathogen 
by heat or by chemical treatment. This destroys the pathogen’s ability to replicate but 
keeps it “intact” so that the immune system can still recognize it. Maintaining the 
epitope structure on the epitope antigen during inactivation is critical. Heat inactiva-
tion is generally unsatisfactory because it results in extensive denaturation of the 
protein; therefore, any epitope that is dependent on higher levels of protein structure 
may change significantly. Chemical inactivation with formaldehyde or formalin has 
been successful. The Salk polio vaccine is produced by formaldehyde inactivation.
Because killed or inactivated pathogens cannot replicate at all, they cannot 
revert to a more virulent form capable of causing disease (as discussed above with 
live attenuated vaccines). Attenuated vaccines generally require only one dose to 
induce long-lasting immunity. However, inactivated vaccine tends to provide a 
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shorter length of protection than live vaccines and is more likely to require boosters 
to create long-term immunity.
A vaccine consisting of orally administered killed cholera bacteria with or with-
out the B subunit of cholera toxin has been developed [15]. Formalin-inactivated 
whole-cell pertussis vaccine was tested by Madsen [16], and later it was shown to be 
relatively successful in controlling severe disease [17]. In 1923, Glenny and Hopkins 
reduced the toxicity of diphtheria toxin by formalin treatment [18]. Ramon has 
improved this finding and has shown that it is possible to inactivate the toxicity of 
these molecules while retaining their ability to induce toxin-neutralizing antibodies 
[19]. In the twentieth century, chemical inactivation was also applied to viruses. 
Influenza vaccine was the first successful inactivated virus vaccine [20].
Inactivated whole bio vaccines still present certain risks, even if they contain 
killed pathogens. When formaldehyde failed to kill all viruses in both vaccine 
batches, serious complications of the first Salk vaccines occurred, which led to a 
high proportion of polio (poliomyelitis).
Inactivated vaccines are used to protect against:
• hepatitis A;
• flu (shot only);
• polio (shot only); and
• rabies.
2.3 Subunit, recombinant, polysaccharide, and conjugate vaccines
The first vaccine, the smallpox vaccine, consists of live attenuated viruses, but 
it does not cause disease in human hosts. Many of the vaccines used today, includ-
ing measles vaccines, yellow fever vaccine, and some influenza vaccines, use live 
attenuated viruses. Others use inactivated forms of toxins made from killed form of 
virus, debris of bacteria, or bacteria. The killed virus, bacterial debris, and inacti-
vated toxins will not cause disease but will still cause immune reactions and prevent 
future infections. However, new techniques are also being developed to make differ-
ent types of vaccines.
Subunit, recombinant, polysaccharide, and conjugate vaccines are biosynthetic 
vaccines. Biosynthetic vaccines contain man-made substances that are very similar 
to pieces of the virus or bacteria. The hepatitis B vaccine is an example.
Since these vaccines use only specific pieces of the germ, they show a very strong 
immune response, which targets the main part of the germ. It can also be used by 
almost everyone who needs them, including people with weakened immune system 
and long-term health problems. Vaccines consisting of specific purified molecules 
derived from pathogens can avoid some of the risks associated with attenuated or 
killed organism vaccines.
One limitation of these vaccines is that you may need booster shots to get ongo-
ing protection against diseases.
Subunit vaccines use only a subset of target pathogens to stimulate the immune 
system’s response. This can be done by isolating a specific protein from the pathogen 
and presenting it separately as an antigen. Acellular pertussis vaccines and influ-
enza vaccines (injected forms) are examples of subunit vaccines.
Another subunit vaccine can be created by genetic engineering. The gene 
encoding the vaccine protein is inserted into another virus or inserted into a 
cultured production cell. Vaccine proteins are also produced when the vector virus 
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is propagated. The result of this approach is a recombinant vaccine: the immune 
system will recognize the expressed protein and provide future protection against 
the target virus. Many genes encoding surface antigens from viral, bacterial, and 
protozoal pathogens have been successfully cloned into bacterial, yeast, insect, or 
mammalian expression systems, and the expressed antigens are used for vaccine 
development. A hepatitis B vaccine that is approved for use in humans is a recom-
binant vaccine. The vaccine was developed by cloning the hepatitis B virus surface 
antigen (HBsAg) gene and expressing it in yeast cells. Recombinant yeast cells 
proliferate in large fermenters, and HBsAg accumulates in cells. At the end of the 
fermentation, recombinant HBsAg are harvested by disrupting yeast cells, which is 
then purified by biochemical techniques. This recombinant hepatitis B vaccine has 
been shown to induce the production of protective antibodies [21, 22].
Human papillomavirus (HPV) vaccine is another vaccine made using genetic 
engineering. Two types of HPV vaccine are available, Gardasil (marketed by Merck 
and protecting against types 6, 11, 16, and 18 of the human papillomavirus) and 
Cervarix (marketed by GlaxoSmithKline and protecting against types 16 and 18 
only). Both are made in the same way: for each strain, a single viral protein was iso-
lated. When these proteins are expressed, viruslike particles (VLPs) are produced. 
These VLPs contain no genetic material that causes disease but promote immune 
responses and protect future HPV infection.
Recombinant vector vaccines use attenuated viruses (or bacterial strains) as 
vectors. A gene encoding a major antigen of a particularly virulent pathogen can be 
introduced into an attenuated virus or bacterium. The attenuated organism acts as a 
vector that replicates and expresses the gene product of the pathogen in the host.
Baculovirus which is a virus that infects only insects can be used as a vector, and 
genes for specific immunogenic surface proteins of influenza virus can be inserted. 
Once the modified virus is introduced into humans, the immunogen is expressed and 
displayed, producing an immune response against the immunogen and producing an 
immune response to the immunogen from which it is derived. In addition to insect 
viruses, human adenoviruses have been identified as potential carriers for recombinant 
vaccines, particularly against diseases such as AIDS. Vaccinia virus, the attenuated 
vaccine used to eradicate smallpox, was the first used in live recombinant vaccine 
approaches [23]. This large, complex virus, with a genome of about 200 genes, can be 
designed to carry dozens of foreign genes without compromising their ability to infect 
host cells and replicate. Experimental recombinant vaccinia strains have been designed 
to provide protection against influenza, rabies, and hepatitis B and other diseases.
DNA vaccines consist of plasmid DNA encoding antigenic proteins which are 
injected directly into the muscle of the recipient. The DNA itself inserts into the 
individual’s cells, which then produce the antigen from the infectious agent. DNA 
vaccines have advantages over many existing vaccines. For example, the encoded 
protein is a native form of the host and has no denaturation or alteration. Therefore, 
the immune response is identical to the antigen expressed by the pathogen. The 
handling and storage of plasmid DNA do not require refrigeration, a feature that 
greatly reduces the cost and complexity of delivery. At present, there are human 
trials underway with several different DNA vaccines, including those for malaria, 
AIDS, influenza, and herpesvirus. Researchers hope that DNA vaccines can produce 
immunity against parasitic diseases such as malaria; however, there is currently no 
human vaccine in use for fighting parasites [24].
Conjugate vaccines are somewhat similar to recombinant vaccines: they are 
prepared using a combination of two different components. The conjugate vac-
cine was prepared using fragments from the coats of bacteria. These coatings are 
chemically linked to a carrier protein which is used as a vaccine. Conjugate vaccines 
are used to produce a more powerful co-immune response: in general, the presented 
Vaccines - The History and Future
6
“fragments” of the bacteria do not themselves produce a strong immune response, 
while the carrier protein produces a strong immune response. This fragment of 
bacterium does not cause disease, but when combined with carrier proteins, it 
can produce immunity against future infections. The vaccines currently in use for 
children against pneumococcal bacterial infections are made using this technique.
These vaccines are used to protect against:
• Haemophilus influenzae type b (Hib) disease;
• hepatitis B;
• human papillomavirus (HPV);
• whooping cough (part of the DTaP combined vaccine);
• pneumococcal disease;
• meningococcal disease; and
• shingles.
2.4 Toxoid vaccines
Toxoid vaccines are made from selected toxins that have been sufficiently 
attenuated and are able to induce a humoral immune response. These toxins 
produce many of the symptoms of the disease. For example, diphtheria and 
tetanus vaccines can be prepared by purifying bacterial toxins and then inac-
tivating toxin with formaldehyde to form a toxoid. Inoculating with a toxoid 
induces an anti-toxoid antibody that is also capable of binding toxins and 
neutralizing their effects.
Toxoid vaccines tend not to have a duration of immunity comparable to attenuated 
viral vaccines; therefore, toxid vaccines, like some other types of vaccines, may need 
booster shots to get ongoing protection against diseases. Revaccination (booster) may 
be required multiple times in a single year depending on individual patient risk factors.




There are still the needs for vaccines against other diseases. Millions of people 
worldwide die of malaria, tuberculosis, and AIDS every year, among which there 
are no effective disease vaccine. The road to successful development of vaccines 
that can be approved for human use, reasonably manufactured cost, and effective 
delivery to high-risk groups is expensive, long, and tedious.
Researchers continue to develop new vaccine types and improve current 
approaches.
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